Senior Manager, Process Sciences

This role is considered On-Site.

Overview

This position will be a part of the CMC Drug Substance Process Sciences group, leading a small team. This role will include process development, in-house non-GMP manufacturing of siRNA and process transfer to CMOs.

This position is fully onsite and will be primarily located in Cambridge, MA.

Key Responsibilities

• Leading/supporting in-house oligonucleotide manufacturing process development and APIs manufacture in non-GMP environment
• Authoring/Supporting drafting/reviewing/ data verifying SOPs, manufacturing and regulatory filing documents according to procedural and regulatory guidelines.
• Supporting process transfer activities and providing timely technical support for GMP productions
• Leading and supporting capability/ building projects
• Leading a CMC Team for Early-Stage Programs from DC approval to end of Phase 2 clinical
• Managing day-to-day lab operations and data/equipment maintenance
• Training, mentoring and managing junior team members
• Participating and representing Process Sciences at cross-functional meetings
• Coordinating material inventory and related activities

Qualifications

• PhD with minimum of 5 years of experience in oligonucleotide chemistry or relevant areas. Experience in an industrial setting is preferred.
• Expertise in solid phase synthesis and hands-on operational knowledge and experience with using and trouble-shooting of DNA/RNA automated solid-phase synthesizers required.
• Knowledge of the analytical and purification techniques for oligonucleotides and oligonucleotide-conjugates is preferred.
• Demonstrated experience leading a team.

About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.